Vertex Pharmaceuticals Inc

Day range

$521.30 – $537.81

Open

$527.18

Prev close

$535.17

Volume

1.64M

Market cap

$135.64B

Shares out

253.81M

P/E

30.79

P/S

10.78

P/B

6.70

P/FCF

35.73

ROE

21.8%

ROA

16.1%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 22, 2026

• Board of directorsOct 20, 2026

  On October 20, 2026, Daniel Brennan was appointed as a new member of the board of directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company"). In connection with the appointment of Mr. Brennan, the size of the Board was increased from ten to eleven members. Mr. Brennan also has joined our Audit and Finance Committee.

• Executive leadershipSep 1, 2026

  In connection with Mr. Poole's appointment, Charles F. Wagner, Jr., the Company's Executive Vice President and Chief Operating & Financial Officer, will cease serving as Chief Financial Officer as of the Effective Date, but will remain Executive Vice President and Chief Operating Officer.

• Deal agreementsJul 7, 2026

  On July 6, 2026, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ('Parent'), Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ('Merger Sub'), and Crinetics Pharmaceuticals, Inc., a Delaware corporation (the 'Company'), entered into an Agreement and Plan of Merger (the 'Merger Agreement'). Subject to the terms of the Merger Agreement, Merger Sub will be merged with and into the Company (the 'Merger'), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

• Shareholder activismMay 13, 2026

  Proposal No. 5: Based upon the following votes, the shareholders approved a shareholder proposal regarding shareholder right to act by written consent: For 126,892,696 | Against 95,756,148 | Abstain 348,792 | Non-Votes 10,337,217.

• Board of directorsApr 29, 2026

  On April 28, 2026, Suketu Upadhyay informed the board of directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") of his decision not to stand for re-election as a director of the Company at the Company's 2026 annual meeting of shareholders (the "2026 Annual Meeting"). Mr. Upadhyay's decision to depart from the Board was due to scheduling conflicts associated with his new role at Incyte Corporation and did not involve any disagreement with the Company on any matter relating to its operations, policies or practices.

• CRSPCRISPR Therapeutics AG-0.30%
• MRNAModerna, Inc. Common Stock-4.71%
• LLYEli Lilly & Co.-0.27%
• ABBVABBVIE INC.+0.23%
• GOOGAlphabet Inc. Class C Capital Stock-0.84%
• PFEPfizer Inc.-0.39%
• AXSMAxsome Therapeutics, Inc-2.36%
• AMZNAmazon.Com Inc-0.53%

Days to cover

4.2

Short interest

4.5M

Avg volume

1.06M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?
  neutralThe Motley Fool· Oct 23, 2026
• Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
  neutralThe Motley Fool· Oct 22, 2026
• Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
  neutralZacks Investment Research· Oct 20, 2026
• How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
  positiveZacks Investment Research· Oct 20, 2026
• Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It
  positiveThe Motley Fool· Oct 19, 2026